门德尔随机化研究:SGLT2抑制,甲和心力衰竭
Zhiyu Wu1, Shuyao Song1, Jun Lv1,2
1Department of Epidemiology & Biostatistics, Peking University School of Public Health, Beijing, China.
Open heart
|September 1, 2025
概括
- 葡萄糖共运输体2 (SGLT2) 抑制剂与较高的甲水平有关,这反过来又与心力衰竭 (HF) 的风险降低有关. 这表明,乙基卡尼丁可能在SGLT2抑制剂对HF的保护中起作用.
科学领域:
- 心血管研究
- 代谢学
- 药理学
背景情况:
- 建议在心力衰竭 (HF) 治疗中使用-葡萄糖共传递剂2 (SGLT2) 抑制剂.
- 具体的机制,特别是涉及甲基生物标志物,如甲,尚未完全理解.
研究的目的:
- 调查乙基卡尼丁与SGLT2抑制之间的关联.
- 检查乙卡尼丁与发生心力衰竭的风险之间的关系.
主要方法:
- 分析了来自中国Kadoorie生物库的2178名参与者的小组.
- 使用向质谱测量测量了血乙烯基卡尼丁水平.
- 通过孟德尔随机化 (MR) 评估了通过SGLT2抑制对乙烯基卡尼丁的基因预测随机血糖 (RPG) 的影响.
- 考克斯的比例危险模型评估了乙烯和HF风险之间的关联.
主要成果:
- 抑制SGLT2与血乙尼水平的增加有关.
- 较高的乙卡尼丁水平与心力衰竭的风险降低相关.
- 从MR分析中得出的乙卡尼丁评分显示与SGLT2抑制和降低HF风险有关.
结论:
- 孟德尔的随机分析支持SGLT2抑制与甲之间存在关联.
- 乙基卡尼丁与SGLT2抑制和心力衰竭的风险降低有关.
- 这些发现表明,乙卡尼可能会调解SGLT2抑制剂的心脏保护作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434


